Literature DB >> 1281073

Management of dysfunctional uterine bleeding.

C M Farquhar1.   

Abstract

Dysfunctional uterine bleeding, although not usually life-threatening, can cause disruption and discomfort for many women. It has often been poorly researched in the past, possibly because of the difficulty in measuring menstrual blood loss. Several different therapies are available and individual women can choose from a number of options. Nonsteroidal anti-inflammatory drugs such as mefenamic acid or indomethacin will be the first choice for many women as they have few side effects and it is only necessary to take them when menstrual bleeding occurs. When contraception is also required, combined oral contraceptives are helpful. Progestogen and danazol therapy are also effective, although side effects do occur. A new development has been the levonorgestrel-containing intrauterine contraceptive device which has been shown to result in large decreases in menstrual blood loss. For those women who would like a surgical approach but do not want to undergo hysterectomy, the relatively new technique of endometrial resection results either in amenorrhoea or reduced menstrual blood loss in the majority of women.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281073     DOI: 10.2165/00003495-199244040-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  27 in total

Review 1.  Hysteroscopy for the investigation of abnormal uterine bleeding.

Authors:  B V Lewis
Journal:  Br J Obstet Gynaecol       Date:  1990-04

Review 2.  Levonorgestrel-releasing intrauterine device.

Authors:  T Luukkainen; P Lähteenmäki; J Toivonen
Journal:  Ann Med       Date:  1990-04       Impact factor: 4.709

3.  Treatment of dysfunctional uterine bleeding with danazol.

Authors:  I S Fraser
Journal:  Aust N Z J Obstet Gynaecol       Date:  1985-08       Impact factor: 2.100

Review 4.  The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review.

Authors:  N Siddle; P Sarrel; M Whitehead
Journal:  Fertil Steril       Date:  1987-01       Impact factor: 7.329

5.  Effect of fenamates on prostaglandin E receptor binding.

Authors:  M C Rees; R Cañete-Solér; A López Bernal; A C Turnbull
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

Review 6.  Anemia and menstrual blood loss.

Authors:  B J Cohen; Y Gibor
Journal:  Obstet Gynecol Surv       Date:  1980-10       Impact factor: 2.347

7.  Menstrual blood loss--a population study. Variation at different ages and attempts to define normality.

Authors:  L Hallberg; A M Högdahl; L Nilsson; G Rybo
Journal:  Acta Obstet Gynecol Scand       Date:  1966       Impact factor: 3.636

8.  Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen.

Authors:  L Mäkäräinen; O Ylikorkala
Journal:  Br J Obstet Gynaecol       Date:  1986-09

9.  Comparison between mefenamic acid and danazol in the treatment of established menorrhagia.

Authors:  C J Dockeray; B L Sheppard; J Bonnar
Journal:  Br J Obstet Gynaecol       Date:  1989-07

10.  Studies in menorrhagia: (a) mefenamic acid, (b) endometrial prostaglandin concentrations.

Authors:  P J Haynes; A P Flint; H Hodgson; A B Anderson; F Dray; A C Turnbull
Journal:  Int J Gynaecol Obstet       Date:  1980 May-Jun       Impact factor: 3.561

View more
  1 in total

1.  Are women satisfied when using levonorgestrel-releasing intrauterine system for treatment of abnormal uterine bleeding?

Authors:  Nina Mansukhani; Jyothi Unni; Meenakshi Dua; Reeta Darbari; Sonia Malik; Sohani Verma; Sonal Bathla
Journal:  J Midlife Health       Date:  2013-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.